Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 11:54 ET | Source: NeuExcell Therapeutics

NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant Glioma

NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025
November 07, 2024 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...